[Click eStock] "CTCBio, Expected Revenue from Contract Manufacturing of Diagnostic Kits"

[Asia Economy Reporter Park Hyungsoo] Shinhan Financial Investment forecasted on the 3rd that CTC Bio's sales of COVID-19 diagnostic kits will increase.

Researcher Lee Donggeon of Shinhan Financial Investment stated, "Since the first quarter, we have been contract manufacturing COVID-19 diagnostic kits for SD Biosensor and Humasis," adding, "From the second quarter of this year, production capacity will be doubled, increasing the supply volume for SD Biosensor."

He continued, "The average unit price per test for domestic contract manufacturers of COVID-19 rapid antigen kits is estimated to be around 200 to 300 KRW," and analyzed, "Assuming a daily production of 1 million tests, the expected monthly sales amount is approximately 7.5 billion KRW."

He emphasized, "If production expands to around 2 million tests, the expected quarterly sales would be 45 billion KRW," and added, "Considering that CTC Bio's annual sales were about 100 billion KRW on a separate basis, even with conservative estimates, sales will achieve the market expectation of 200 billion KRW."

The researcher added, "The improved new drug division is expected to complete Phase 3 clinical trials in the first half of this year," and noted, "Since it is a non-reimbursable item, it can be launched immediately upon approval."

This content was produced with the assistance of AI translation services.